1. Medtech Insight
  2. >>Device Area
  3. >>Ophthalmology

Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma

 
• By Marion Webb

Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its second-generation minimally invasive glaucoma surgery (MIGS) iStent device used for treating glaucoma, the second-leading cause of blindness.

San Clemente, Calif.-based ophthalmic medical technology company Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its minimally invasive glaucoma surgery (MIGS) iStent inject device used for treating glaucoma.

Glaukos pioneered MIGS devices, which are among the fastest-growing technologies for treating refractive mild to moderate glaucoma by reducing intraocular pressure, or IOP, and the progression of glaucoma. Up until...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ophthalmology

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By Marion Webb

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.

Seonix Bio’s Newly Launched Saliva-Based Genetic Test Aims To Shed Light On Glaucoma Risk Assessment

 
• By Marion Webb

Seonix launched SightScore, the first clinical polygenic risk score test for glaucoma available in the US, and plans to introduce more genetic-based tests for eye conditions such as macular degeneration.

FDA Releases Six More De Novo Summaries

 
• By Elizabeth Orr

The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.